Afatinib (BIBW2992)
Catalog No: CFN60034
Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFRwt, EGFR L858R , EGFR L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Afzelin
Catalog No: CFN98757
Afzelin has several cellular activities such as DNA-protective, antibacterial, antioxidant, and anti-inflammatory as well as UV-absorbing activity and may protect human skin from UVB-induced damage by a combination of UV-absorbing and cellular activities.
Afzelin has potenial anti-cancer activity against prostate cancer, the activity is due to inhibition of LIM domain kinase 021 expression, it can inhibit the proliferation of LNCaP and PC302cells, and block the cell cycle in the G002phase. Afzelin can attenuate asthma phenotypes is based on reduction of Th2 cytokine via inhibition of GATA-binding protein 3 transcription factor, which is the master regulator of Th2 cytokine differentiation and production.
Agnuside
Catalog No: CFN99203
Agnuside has anti-arthritic activity, it also shows inhibition of vascular permeability and leukocyte migration in vivo.It inhibited an array of pro-inflammatory mediators (PGE(2) and LTB(4)) and T-cell-mediated cytokines (IL-2, TNF-α, IFN-γ, IL-4, IL-10, IL-17).
